trends in medication management. - telus health...2. how generic substitution is deployed can have a...

#HealthBenefitsTrends

Trends in medicationmanagement.

Vishal Ravikanti R.Ph

Manager, Professional Services, TELUS Health

2#HealthBenefitsTrends

Content outlinei. Therapy class insights 2018

ii. Legislative update

iii. Biosimilars & subsequent entry products

iv. Drug pipeline

Therapy class insights

2018


Top 10 drug classes by adjudicated amountOntario

Therapeutic class

Rank by total

adjudicated amount

Percent of total

adjudicated amount

2018 2017 2018 2017

Diabetes 1 2 11.7% 10.3%

Rheumatoid arthritis 2 1 10.9% 11.1%

Skin disorders 3 3 6.5% 5.6%

Cancer 4 5 6.0% 4.9%

Asthma 5 4 5.4% 5.6%

Depression 6 7 4.3% 4.6%

Blood pressure 7 6 4.2% 4.7%

Ulcers 8 8 3.7% 3.8%

Cholesterol disorders 9 9 3.2% 3.4%

Multiple sclerosis 10 13 3.1% 2.8%

% of total adjudicated amount 59% 56.8%


Top 10 products by adjudicated amountOntario

Drug name

Rank by total

adjudicated amount

Percent of total

adjudicated amount

2018 2017 2018 2017

Remicade 1 1 3.7% 4.3%

Humira 2 2 3.5% 3.4%

Insulin 3 3 1.8% 2.0%

Stelara 4 7 1.7% 1.3%

Enbrel 5 4 1.4% 1.6%

Crestor 6 5 1.4% 1.5%

Nexium 7 6 1.4% 1.4%

Janumet 8 10 1.1% 1.0%

Victoza 9 13 0.9% 0.9%

Symbicort 10 12 0.9% 0.9%

% of adjudicated amount 17.8% 18.3%


Therapy class insights

Diabetes

What is happening outside of the top 10?

Impact of generic substitution type

Therapeutic class

Rank by total

adjudicated amount

Percent of total

adjudicated amount

2018 2017 2018 2017

HIV 16 14 1.9% 2.2%

Migraine 25 28 1.2% 1.1%


$990

$839 $1,213

0 $

5,000,000 $

10,000,000 $

15,000,000 $

20,000,000 $

25,000,000 $

30,000,000 $

35,000,000 $

40,000,000 $

45,000,000 $

50,000,000 $

2014 2015 2016 2017 2018

INSULIN CLASS -14,6% JANUMET 19,3% JARDIANCE 88,1%

GLP1 CLASS 32,2% INVOKANA -13,7% FREESTYLE LIBRE 2160 %

Total eligible cost 2018: $221 M (+10,1 %)

$1,693

Diabetes: Trends in medication use

$907 $728

To

tal e

ligib

le c

osts

-O

nta

rio

Suggested management: step therapy


97%91%

0%

20%

40%

60%

80%

100%

Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018

Generic Truvada

Generic Viread

Generic Atripla

Number of claimants (Ontario)

Outside the top 10: New HIV generics

1 902

1 237

159

Generi

c u

tiliz

ation

(Onta

rio)

Health Canada

approved generics

Suggested management: generic substitution


100 $

125 $

150 $

175 $

200 $

Jan 2018 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan-19 Feb

Triptan Only Total Migraine

November 2018: First CGRP inhibitor claim on TELUS BoB

Outside the top 10: Migraine – impact of new entrant A

ve

rage e

ligib

le c

ost p

er

cla

ima

nt

(On

tario)

$147

$156

Suggested management: prior authorization / generic substitution / managed formulary


0 $

200 $

400 $

None Regular Mandatory

Brand Crestor Generic Crestor

$135

$27

$412

Impact of generic substitution type – Crestor A

ve

rage e

ligib

le c

ost p

er

cla

ima

nt

(On

tario)

Generic substitution type

Suggested management: mandatory generic substitution

Legislative update


National pharmacare

Advisory council introduced

February

2018

Finance Minister Morneau speech

House of commons

report

Advisory council consultation sessions & townhalls

Interim report from the advisory

council & federal budget released

Advisory council’s final

report anticipated

March

2018

April

2018

July-

October

2018

March

2019

Spring

2019


National pharmacare

Interim report & budget 2019

Foundational recommendations for national pharmacare

1. Creation of a national drug agency: Canadian Drug Agency

2. Comprehensive, evidence-based national formulary

3. Invest in drug data and information technology (IT) systems

4. National strategy for high cost drugs for rare diseases


OHIP+: program changes

As of April 1, 2019 eligibility changes for OHIP+ have taken effect.

Children and youth, 24 years of age and under, are no longer eligible for

OHIP+ if they are covered by a private insurance plan.

Prior authorization transition plan.

What can we expect going forward?


$0

$4,000,000

$8,000,000

$12,000,000

$16,000,000

$20,000,000

$24,000,000

Jan2017

Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan2018

Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

OHIP+ implementation Total 2017 : $244.6M

Total 2018 : $121.9M

OHIP+: pre & post implementation T

ota

l e

ligib

le c

osts

Biosimilars & subsequent

entry products


National uptake - TELUS BoB experience

Biosimilar brand name(chemical entity; reference brand)

Price

difference vs.

reference

drug

% of claimants % of total eligible cost

2016 2017 2018 2016 2017 2018

GRASTOFIL(filgrastim; Neupogen)

-17% 0.96% 31.34% 57.82% 0.40% 23.66% 49.27%

INFLECTRA(infliximab; Remicade)

-46% 0.84% 3.83% 8.12% 0.36% 1.48% 3.94%

BRENZYS & ERELZI (etanercept; Enbrel)

-37% 0.09% 2.70% 9.24% 0.01% 1.00% 4.53%

BASAGLAR(insuline glargine; Lantus)

-25% 0.56% 1.66% 3.97% 0.22% 0.76% 1.93%

GLATECT(glatiramer; Copaxone)

-29% - - 2.27% - - 0.69%


Market share of infliximab

Inflectra, Renflexis - Ontario

0.0%

1.0%

2.0%

3.0%

4.0%

5.0%

6.0%

7.0%

8.0%

Jan2016




% of claimants % of total eligible cost

Inflectra added to ODB

(limited use benefit)

Renflexis added to ODB

(limited use benefit)

6.87%

* Renflexis (infliximab) : 1st claim in December 2018

Ma

rke

t sh

are

(O

nta

rio

)


Market share of insulin glargine

Basaglar – Ontario

0.0%

1.0%

2.0%

Jan2016




% of claimants % of total eligible costBasaglar added to ODB

(general benefit)

Ma

rke

t sh

are

(O

nta

rio

)

2.05%


Market share of insulin glargine

Basaglar/Toujeo – Ontario

0%

5%

10%

15%

20%

Jan2016




Basaglar Toujeo

Ma

rke

t sh

are

(O

nta

rio

)

20.3%

2.05%


Update: biosimilars under reviewExpected launches within the next 3 years

Reference medication Indication(s) Health Canada regulatory status Eligible amount

TELUS BoB 2018

Humira (adalimumab)Rheumatoid arthritis/

inflammatory conditions 1 currently under review - November 2018 $177M

Neupogen (filgrastim) Neutropenia 2 currently under review - April 2018$7.8M (originator)

$9.4M (biosimilar)

Avastin (bevacizumab) Cancer (multiple indications) 2 currently under review - August 2018 $4.2M

Herceptin (trastuzumab) Breast cancer / gastric cancer 7 currently under review - February 2018 $114K

Rituxan (rituximab)

Lymphoma / leukemia /

rheumatoid arthritis / GPA &

MPA

4 currently under review - April 2018 $10.9M

Forteo (teriparatide) Osteoporosis 1 currently under review - June 2018 $2.7M

>$212M

Drug pipeline


Biosimilar pipeline

Generic submissions (40 molecules)

Novel oral anticoagulants (Xarelto, Eliquis, Pradaxa)

Multiple sclerosis (Gilenya & Fampyra)

132 submissions (new drugs & new indications)

1/3 are cancer products

New biologics (migraine, osteoporosis)

Expansion of indications

Submissions under review – Health Canada

Cost

drivers

Cost

relief


New drug pipeline – short-term

Drug Indication Potential impact Cost

larotrectinib

Bayer

A kinase inhibitor targeted against solid tumors testing positive

for a mutation known as an NTRK gene fusion.

FDA approval in December 2018 (Vitrakvi) as a tumor

agnostic drug.

Submitted to Health Canada in November 2018

Oral cancer treatment, therefore will

impact private payers. New

paradigm in approval of oncology

products without a specific cancer

type.

U.S. pricing set

between $11,000

and $32,800 per

month (pediatric

and adult dosing).

ataluren

PTC therapeutics

(Europe)

Approved in Europe for the treatment of Duchenne muscular

dystrophy caused by a nonsense mutation.

Submitted to Health Canada in September 2018

Sold as TRANSLARNA in Europe

Would be first treatment approved

by Health Canada for specific

subset of Duchenne muscular

dystrophy.

Rare disease

pricing expected.

galcanezumab

Eli Lilly

Monoclonal antibody (biologic drug) targeting CGRP indicated

for the prevention of chronic and episodic migraines.

Submitted to Health Canada in October 2018

Aimovig (Novartis) submitted to Health Canada in October

2017, received NOC August 2018

Highly anticipated new drug class

targeting a highly prevalent medical

condition (approx. 8% of

Canadians).

Expected annual

cost up to $7,000.


New indication pipeline – short-term

Drug Indication Potential impact Cost

Dupixent

(dupilumab)

Sanofi-Aventis

Recombinant human IgG4 monoclonal antibody that inhibits

signaling of cytokines involved in atopic disease.

FDA approval for severe asthma indication granted in

October 2018.

Submitted to Health Canada in November 2018

Based on pricing for treatment of

atopic dermatitis, Dupixent would be

a costly alternative to exisiting

biologic alternatives in severe

asthma.

Annual cost

approximately

$30,000.

Keytruda

(pembrolizumab)

Merck

Currently approved in Canada for Melanoma, NSCLC,

Hodgkin Lymphoma, Primary Mediastinal B-cell Lymphoma,

Urothelial Carcinoma.

Submitted to Health Canada from September 2017 to

October 2018

FDA approval for tumor agnostic indication based on

common biomarker rather than tumor type

Traditional treatment indications

based on tumor type potentially

seeking tumor agnostic approval.

New paradigm in approval of

oncology products without a specific

cancer type.

Approximately

$8,800 per

treatment cycle.


Summary

1. Therapy classes outside of the top 10 are evolving

2. How generic substitution is deployed can have a large impact

3. National pharmacare: advisory council final report – spring 2019

4. Use of biosimilar and subsequent entry products growing slowly

5. New drugs/indications under review both drive costs and provide relief

#HealthBenefitsTrends

trends in medication management. - telus health...2. how generic substitution is deployed can have a...

Documents